Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 15/20 | 0.41 |
| ▸ | MPL | P40238 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428741 | 0.96 | MAPKAPK2 (0.40) | MAPKAPK2MPLCYP11B2HCRTR1HCRTR2 | |
| SCHEMBL429915 | 0.89 | MAPKAPK2 (0.47) | MAPKAPK2CYP11B2CYP3A4 | |
| SCHEMBL431848 | 0.89 | MAPKAPK2 (0.41) | MAPKAPK2 | |
| SCHEMBL429846 | 0.87 | MAPKAPK2 (0.40) | MAPKAPK2CYP11B2 | |
| SCHEMBL431381 | 0.86 | MAPKAPK2 (0.40) | MAPKAPK2CYP11B2 | |
| SCHEMBL424661 | 0.86 | MAPKAPK2 (0.40) | MAPKAPK2MPL | |
| SCHEMBL426085 | 0.86 | MAPKAPK2 (0.46) | MAPKAPK2CYP11B2 | |
| SCHEMBL428962 | 0.86 | MAPKAPK2 (0.38) | MAPKAPK2MPL | |
| SCHEMBL430553 | 0.84 | MAPKAPK2 (0.39) | MAPKAPK2CYP11B2 | |
| SCHEMBL426415 | 0.83 | MAPKAPK2 (0.57) | MAPKAPK2MPLCYP11B2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| CN-101687869-A | Tetracyclic lactam derivatives as MK2 inhibitors | NOVARTIS AG | 2010-03-31 | — | — | CN | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | MAPKAPK2 480/4885MPL 132/4885CYP11B2 2079/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | MAPKAPK2 480/4885MPL 132/4885CYP11B2 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.